Scholars Central

Conference abstractPublished 4 Dec 2017

Alzheimers drug discovery: Targeting synaptic glutamate uptake

Authors: Markku Kurkinen

Wayne State University, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

According to the amyloid hypothesis, Alzheimer dementia begins in the brain with AÃ?² peptides accumulation and amyloid formation. However, clinical trials targeting AÃ?² peptides and brain amyloid have failed to help anybody living with Alzheimer. Instead of repeating similar trials and errors of 25 years, we have to discover novel drug targets and better our research to prevent and treat Alzheimer. Glutamate is the synaptic signaling molecule of neurons. As soon as the glutamate signaling starts it is stopped in 0.1- 2 ms by astrocytes, which take up and clear glutamate from synapses. This prevents glutamate neurotoxicity causing synapse loss and neuron cell death. Astrocytes make EAAT2 (excitatory amino acid transporter-2), the major glutamate transporter and 1% of brain protein. In Alzheimer, astrocytes are impaired in synaptic glutamate uptake. In experimental mouse models of Alzheimer, increasing EAAT2 expression slows dementia progression. Here, I describe a simple assay for drugs that activate EAAT2 in glutamate uptake. The assay targets the EAAT2 protein reconstituted in liposomes and measures glutamate uptake with Oxonol VI red fluorescent dye. By directly targeting EAAT2, the assay should limit âÂ?Â?off-targetingâÂ?Â? of drugs and adverse events, which are the main problems in AlzheimerâÂ?Â?s drug discovery and clinical development. For efficacy, specificity and safety, EAAT2 activating drugs are studied in experimental C. elegans models of Alzheimer.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Alzheimers Disease & Parkinsonism.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Alzheimers Disease & Parkinsonism
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Markku Kurkinen”